Meta-analysis confirms rasagiline efficacy in Parkinson's disease
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- Rasagiline (Azilect), a selective inhibitor of monoamine oxidase B, reduces a variety of symptoms of Parkinson's disease.
Why this matters
- Individual trials of rasagiline for Parkinson's disease have generally been small.
- Relative to peers given placebo, pa...